Valera Shooting To Return Valstar To U.S. Market By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Valrubicin was pulled from the market in 2002 due to supply issues regarding a key ingredient.
You may also be interested in...
Indevus Plans To Relaunch Valstar By Year-End
Company announces submission of an sNDA for bladder cancer treatment, which was pulled from the market in 2002 due to manufacturing issues.
Indevus Plans To Relaunch Valstar By Year-End
Company announces submission of an sNDA for bladder cancer treatment, which was pulled from the market in 2002 due to manufacturing issues.
Indevus Gains Supprelin LA With Purchase Of Valera
Indevus also expects to out-license Valera's early stage pipeline, as well as several of its own products.